Literature DB >> 19809816

Correlation of ESR, C3, C4, anti-DNA and lupus activity based on British Isles Lupus Assessment Group Index in patients of rheumatology clinic.

Siavash Nasiri1, Mansoor Karimifar, Zahra Sayed Bonakdar, Mansour Salesi.   

Abstract

This study aimed to determine the correlation between of ESR, C3, C4, anti-DNA, and lupus activity and also the construct and criterion validity of the British Isles Lupus Assessment Group (BILAG) index for assessing disease activity in systemic lupus erythematosus (SLE). Patients with SLE were recruited into a cross-sectional study. Data were analyzed for estimating of SLE disease activity [scores on the BILAG index and Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K)]. Overall BILAG scores were determined by the highest score achieved in any of the individual systems in the respective index. Erythrocyte sedimentation rates (ESRs), C3 levels, C4 levels, anti-double-stranded DNA (anti-dsDNA) levels, and SLEDAI-2K scores were used in the analysis of construct validity. Statistical analyses were performed using ordinal logistic regression for construct validity. Of the 100 patients with SLE, 90% were women. Their mean ± SD age was 31.1 ± 9.8 years. Increasing overall scores on the BILAG index were associated with increasing ESRs, decreasing C3 levels, decreasing C4 levels, elevated anti-dsDNA levels, and increasing SLEDAI-2K scores (all P < 0.01). These findings show that the ESR, C3, C4, and anti-DNA should be used in the evaluation and management of patients with SLE. Also the results show that the BILAG index has construct validity.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19809816     DOI: 10.1007/s00296-009-1201-3

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  20 in total

1.  A note on robust variance estimation for cluster-correlated data.

Authors:  R L Williams
Journal:  Biometrics       Date:  2000-06       Impact factor: 2.571

2.  BILAG 2004. Development and initial validation of an updated version of the British Isles Lupus Assessment Group's disease activity index for patients with systemic lupus erythematosus.

Authors:  D A Isenberg; A Rahman; E Allen; V Farewell; M Akil; I N Bruce; D D'Cruz; B Griffiths; M Khamashta; P Maddison; N McHugh; M Snaith; L S Teh; C S Yee; A Zoma; C Gordon
Journal:  Rheumatology (Oxford)       Date:  2005-04-06       Impact factor: 7.580

3.  The genetic basis of Ro and La antibody formation in systemic lupus erythematosus. Results of a multicenter study. The SLE Study Group.

Authors:  K Hartung; H Ehrfeld; H J Lakomek; R Coldewey; B Lang; F Krapf; R Müller; D Schendel; H Deicher; H P Seelig
Journal:  Rheumatol Int       Date:  1992       Impact factor: 2.631

4.  Crosscultural validation and reliability of 3 disease activity indices in systemic lupus erythematosus.

Authors:  D D Gladman; C H Goldsmith; M B Urowitz; P Bacon; C Bombardier; D Isenberg; K Kalunian; M H Liang; P Maddison; O Nived
Journal:  J Rheumatol       Date:  1992-04       Impact factor: 4.666

5.  Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus.

Authors:  M C Hochberg
Journal:  Arthritis Rheum       Date:  1997-09

Review 6.  Measurement of systemic lupus erythematosus activity in clinical research.

Authors:  M H Liang; S A Socher; W N Roberts; J M Esdaile
Journal:  Arthritis Rheum       Date:  1988-07

7.  Revised British Isles Lupus Assessment Group 2004 index: a reliable tool for assessment of systemic lupus erythematosus activity.

Authors:  Chee-Seng Yee; Vernon Farewell; David A Isenberg; Athiveeraramapandian Prabu; Katharina Sokoll; Lee-Suan Teh; Anisur Rahman; Ian N Bruce; Bridget Griffiths; Mohammed Akil; Neil McHugh; David D'Cruz; Munther A Khamashta; Simon Bowman; Peter Maddison; Asad Zoma; Elizabeth Allen; Caroline Gordon
Journal:  Arthritis Rheum       Date:  2006-10

8.  Ro(SS-A) positive Sjogren's/lupus erythematosus (SC/LE) overlap patients are associated with the HLA-DR3 and/or DRw6 phenotypes.

Authors:  T T Provost; N Talal; W Bias; J B Harley; M Reichlin; E L Alexander
Journal:  J Invest Dermatol       Date:  1988-10       Impact factor: 8.551

9.  Defining response in systemic lupus erythematosus: a study by the Systemic Lupus International Collaborating Clinics group.

Authors:  Sean J Wollaston; Vernon T Farewell; David A Isenberg; Caroline Gordon; Joan T Merrill; Michelle A Petri; Kenneth C Kalunian
Journal:  J Rheumatol       Date:  2004-12       Impact factor: 4.666

10.  Sensitivity to change of 3 Systemic Lupus Erythematosus Disease Activity Indices: international validation.

Authors:  D D Gladman; C H Goldsmith; M B Urowitz; P Bacon; C Bombardier; D Isenberg; K Kalunian; M H Liang; P Maddison; O Nived
Journal:  J Rheumatol       Date:  1994-08       Impact factor: 4.666

View more
  9 in total

1.  Beneficial effect of Eucommia polysaccharides on systemic lupus erythematosus-like syndrome induced by Campylobacter jejuni in BALB/c mice.

Authors:  Long Jiang; Zheng Wang; Hong-Wei Zhu; Hong-Ye Di; Hong Li; Yun-Yi Zhang; Dao-Feng Chen
Journal:  Inflammation       Date:  2011-10       Impact factor: 4.092

2.  Insulin resistance in children with juvenile systemic lupus erythematosus and ınvestigation of the possibly responsible factors.

Authors:  Gürkan Tarçın; Hasan Karakaş; Sezgin Şahin; Hande Turan; Mehmet Yıldız; Yavuz Özer; Fatih Haşlak; Dilek Bingöl Aydın; Amra Adroviç; Kenan Barut; Özgür Kasapçopur; Oya Ercan
Journal:  Clin Rheumatol       Date:  2021-10-07       Impact factor: 2.980

3.  Erythrocyte sedimentation rate is a predictor of renal and overall SLE disease activity.

Authors:  G Stojan; H Fang; L Magder; M Petri
Journal:  Lupus       Date:  2013-06-11       Impact factor: 2.911

Review 4.  Urine biomarkers in juvenile-onset SLE nephritis.

Authors:  Louise Watson; Michael W Beresford
Journal:  Pediatr Nephrol       Date:  2012-05-16       Impact factor: 3.714

5.  Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response.

Authors:  Ronald F van Vollenhoven; Michelle A Petri; Ricard Cervera; David A Roth; Beulah N Ji; Christi S Kleoudis; Z John Zhong; William Freimuth
Journal:  Ann Rheum Dis       Date:  2012-02-15       Impact factor: 19.103

6.  Efficacy and safety of belimumab/low-dose cyclophosphamide therapy in moderate-to-severe systemic lupus erythematosus.

Authors:  Hao Cheng; Xiao-Ying Zhang; Hui-Dan Yang; Zhen Yu; Cheng-Lan Yan; Chong Gao; Hong-Yan Wen
Journal:  Front Immunol       Date:  2022-08-01       Impact factor: 8.786

7.  Mannose binding lectin: a biomarker of systemic lupus erythematosus disease activity.

Authors:  Aditya K Panda; Jyoti R Parida; Rina Tripathy; Sarit S Pattanaik; Balachandran Ravindran; Bidyut K Das
Journal:  Arthritis Res Ther       Date:  2012-10-15       Impact factor: 5.156

8.  Double positive CD4+CD8+ T cells: key suppressive role in the production of autoantibodies in systemic lupus erythematosus.

Authors:  Yongkang Wu; Bei Cai; Weihua Feng; Bin Yang; Zhuochun Huang; Chuan Zuo; Lanlan Wang
Journal:  Indian J Med Res       Date:  2014-10       Impact factor: 2.375

9.  Elevated BLyS levels in patients with systemic lupus erythematosus: Associated factors and responses to belimumab.

Authors:  D A Roth; A Thompson; Y Tang; A E Hammer; C T Molta; D Gordon
Journal:  Lupus       Date:  2015-09-18       Impact factor: 2.911

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.